AU576907B2
(en)
*
|
1984-11-01 |
1988-09-08 |
American Home Products Corporation |
Oral vaccines comprising live recombinant adenoviruses
|
FR2642767B1
(fr)
*
|
1989-01-19 |
1993-10-01 |
Transgene Sa |
Vecteurs d'expression de proteines heterologues dans les cellules eucaryotes, lignees cellulaires obtenues et procede pour leur preparation
|
US5670488A
(en)
*
|
1992-12-03 |
1997-09-23 |
Genzyme Corporation |
Adenovirus vector for gene therapy
|
US20020164782A1
(en)
|
1999-02-10 |
2002-11-07 |
Gregory Richard J. |
Adenovirus vectors for gene therapy
|
US6099831A
(en)
*
|
1992-09-25 |
2000-08-08 |
Centre National De La Recherche Scientifique |
Viral recombinant vectors for expression in muscle cells
|
FR2681786A1
(fr)
*
|
1991-09-27 |
1993-04-02 |
Centre Nat Rech Scient |
Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.
|
US6743623B2
(en)
|
1991-09-27 |
2004-06-01 |
Centre National De La Recherche Scientifique |
Viral recombinant vectors for expression in muscle cells
|
US6013638A
(en)
*
|
1991-10-02 |
2000-01-11 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
|
FR2688514A1
(fr)
*
|
1992-03-16 |
1993-09-17 |
Centre Nat Rech Scient |
Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
|
EP0673431A1
(de)
*
|
1992-12-03 |
1995-09-27 |
Genzyme Corporation |
GENTHERAPIE DER MYKOVISCIDOSES (kystic fibroses)
|
FR2707880B1
(fr)
*
|
1993-06-30 |
1995-10-06 |
Rhone Poulenc Rorer Sa |
Compositions pharmaceutiques et leur utilisation, notamment pour le traitement des maladies neurodégénératives.
|
FR2711670B1
(fr)
|
1993-10-22 |
1996-01-12 |
Pasteur Institut |
Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
|
US5820868A
(en)
*
|
1993-12-09 |
1998-10-13 |
Veterinary Infectious Disease Organization |
Recombinant protein production in bovine adenovirus expression vector system
|
IL113052A0
(en)
|
1994-03-23 |
1995-06-29 |
Rhone Poulenc Rorer Sa |
Recombinant viruses, their preparation and their use in gene therapy
|
FR2730637B1
(fr)
|
1995-02-17 |
1997-03-28 |
Rhone Poulenc Rorer Sa |
Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
|
FR2732357B1
(fr)
|
1995-03-31 |
1997-04-30 |
Rhone Poulenc Rorer Sa |
Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose
|
ES2333425T5
(es)
|
1995-06-15 |
2012-08-28 |
Crucell Holland B.V. |
Sistemas de empaquetado para adenovirus recombinante humano destinados a terapia génica
|
AU750891B2
(en)
|
1996-12-06 |
2002-08-01 |
Aventis Pharmaceuticals Inc. |
Polypeptides encoded by a human lipase-like gene, compositions and methods
|
US7008776B1
(en)
|
1996-12-06 |
2006-03-07 |
Aventis Pharmaceuticals Inc. |
Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
|
US6884430B1
(en)
|
1997-02-10 |
2005-04-26 |
Aventis Pharma S.A. |
Formulation of stabilized cationic transfection agent(s) /nucleic acid particles
|
CN1177934C
(zh)
|
1997-04-28 |
2004-12-01 |
阿文蒂斯药物股份有限公司 |
腺病毒介导的肿瘤内投送血管生成拮抗剂用于肿瘤的治疗
|
WO1998059063A2
(en)
|
1997-06-23 |
1998-12-30 |
University Of Saskatchewan |
Bovine adenovirus type 3 genome
|
DE69826124T3
(de)
|
1997-06-30 |
2007-10-11 |
Institut Gustave Roussy |
Verabreichung der nukleinsäure in den quergestreiften muskel
|
US6653088B1
(en)
|
1997-10-24 |
2003-11-25 |
Aventis Pharma S.A. |
Interaction test for the investigation of inhibitory molecules of the interaction between a presenilin and the β-amyloid peptide
|
US6225456B1
(en)
|
1998-05-07 |
2001-05-01 |
University Technololy Corporation |
Ras suppressor SUR-5
|
US6506889B1
(en)
|
1998-05-19 |
2003-01-14 |
University Technology Corporation |
Ras suppressor SUR-8 and related compositions and methods
|
US6441156B1
(en)
|
1998-12-30 |
2002-08-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Calcium channel compositions and methods of use thereof
|
US7604960B2
(en)
|
1999-04-15 |
2009-10-20 |
Crucell Holland B.V. |
Transient protein expression methods
|
EP1533380B1
(de)
*
|
1999-04-15 |
2009-11-04 |
Crucell Holland B.V. |
Verwendung von Rekombinanten Proteinen in Menschlichen Zellen
|
US8236561B2
(en)
|
1999-04-15 |
2012-08-07 |
Crucell Holland B.V. |
Efficient production of IgA in recombinant mammalian cells
|
US6855544B1
(en)
|
1999-04-15 |
2005-02-15 |
Crucell Holland B.V. |
Recombinant protein production in a human cell
|
US7297680B2
(en)
|
1999-04-15 |
2007-11-20 |
Crucell Holland B.V. |
Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
|
FR2799472B1
(fr)
|
1999-10-07 |
2004-07-16 |
Aventis Pharma Sa |
Preparation d'adenovirus recombinants et de banques adenovirales
|
US7192759B1
(en)
|
1999-11-26 |
2007-03-20 |
Crucell Holland B.V. |
Production of vaccines
|
US7527961B2
(en)
|
1999-11-26 |
2009-05-05 |
Crucell Holland B.V. |
Production of vaccines
|
US7521220B2
(en)
|
1999-11-26 |
2009-04-21 |
Crucell Holland B.V. |
Production of vaccines
|
EP2286799B1
(de)
|
2000-03-24 |
2015-07-29 |
Biosphere Medical, Inc. |
Mikrokugeln zur aktiven Embolisation
|
IL151987A0
(en)
|
2000-03-31 |
2003-04-10 |
Aventis Pharma Inc |
Nuclear factor kb inducing factor
|
GB0018307D0
(en)
|
2000-07-26 |
2000-09-13 |
Aventis Pharm Prod Inc |
Polypeptides
|
DK2364734T3
(en)
|
2000-07-21 |
2017-10-30 |
Revance Therapeutics Inc |
Biological multicomponent transport systems
|
US6916635B2
(en)
|
2000-10-02 |
2005-07-12 |
The Research Foundation Of State University Of New York |
Hybrid adenovirus/adeno-associated virus vectors and methods of use thereof
|
US7060442B2
(en)
|
2000-10-30 |
2006-06-13 |
Regents Of The University Of Michigan |
Modulators on Nod2 signaling
|
EP1355918B9
(de)
|
2000-12-28 |
2012-01-25 |
Wyeth LLC |
Rekombinantes schutzprotein aus streptococcus pneumoniae
|
FR2829136B1
(fr)
|
2001-08-29 |
2006-11-17 |
Aventis Pharma Sa |
Derives lipidiques d'aminoglycosides
|
MX339524B
(es)
|
2001-10-11 |
2016-05-30 |
Wyeth Corp |
Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
|
KR100979025B1
(ko)
|
2001-12-07 |
2010-08-30 |
크루셀 홀란드 비.브이. |
바이러스, 바이러스 단리물 및 백신의 생산
|
EP1479985B1
(de)
|
2002-01-17 |
2017-06-14 |
Alfa Laval Corporate AB |
Getauchter Verdampfer umfassend einen Plattenwärmetauscher und ein zylindrisches Gehäuse in dem der Plattenwärmetauscher angeordnet ist
|
EP2316922B1
(de)
|
2002-05-24 |
2013-05-22 |
Merck Sharp & Dohme Corp. |
Humaner neutraliserender Anti-IGFR Antikörper
|
US7785608B2
(en)
|
2002-08-30 |
2010-08-31 |
Wyeth Holdings Corporation |
Immunogenic compositions for the prevention and treatment of meningococcal disease
|
EP1623023B1
(de)
|
2003-05-09 |
2008-11-12 |
Crucell Holland B.V. |
Kulturen von e1-immortalisierten zellen und verfahren zu deren kultivierung zur erhöhung der produktausbeuten davon
|
US7432057B2
(en)
|
2004-01-30 |
2008-10-07 |
Michigan State University |
Genetic test for PSE-susceptible turkeys
|
JP4772045B2
(ja)
|
2004-07-16 |
2011-09-14 |
アメリカ合衆国 |
Cmv/r核酸コンストラクトを含むaidsに対するワクチン
|
BRPI0714981A2
(pt)
|
2006-07-28 |
2013-08-13 |
Sanofi Aventis |
composiÇço, mÉtodo para fazer a mesma a qual compreende um inibidor que inibe a atividade de uma proteÍna do complexo iii, um veÍculo e um membro da superfamÍlia da fator de necrose de tumor, mÉtodo para conduzir um ensaio para determinar se um composto É um inibidor de atividade de supressço de tnf de uma proteÍna do complexo iii e uso de um composto
|
DK2068922T3
(da)
|
2006-10-19 |
2012-10-08 |
Csl Ltd |
Anti-IL-13Ralfa1-antistoffer samt deres anvendelser
|
PL2829551T3
(pl)
|
2006-10-19 |
2018-04-30 |
Csl Limited |
Antagonisty przeciwciała o wysokim powinowactwie wobec receptora alfa 1 interleukiny-13
|
AR064642A1
(es)
|
2006-12-22 |
2009-04-15 |
Wyeth Corp |
Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
|
EP2331071A1
(de)
|
2008-09-05 |
2011-06-15 |
Institut National De La Sante Et De La Recherche Medicale |
Neue multimodulare anordnung zur intrazellulären abgabe
|
AU2009313615B2
(en)
|
2008-11-05 |
2012-11-29 |
Regents Of The University Of Minnesota |
Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (BHS) disease
|
WO2010096561A1
(en)
|
2009-02-18 |
2010-08-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Synthetic hiv/siv gag proteins and uses thereof
|
PL3246044T5
(pl)
|
2010-08-23 |
2024-06-17 |
Wyeth Llc |
Stabilne preparaty antygenów rLP2086 Neisseria meningitidis
|
MY166172A
(en)
|
2010-09-10 |
2018-06-07 |
Wyeth Llc |
Non-lipidated variants of neisseria meningitidis orf2086 antigens
|
WO2012145509A2
(en)
|
2011-04-19 |
2012-10-26 |
The Research Foundation Of State University Of New York |
Adeno-associated-virus rep sequences, vectors, and viruses
|
MX367842B
(es)
|
2012-02-07 |
2019-09-09 |
Global Bio Therapeutics Inc |
Método compartimentado de administración de ácidos nucleicos y composiciones y usos del mismo.
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
NZ628449A
(en)
|
2012-03-09 |
2016-04-29 |
Pfizer |
Neisseria meningitidis compositions and methods thereof
|
ES2685894T3
(es)
|
2013-03-08 |
2018-10-15 |
Pfizer Inc. |
Polipéptidos de fusión inmunogénicos
|
US10981961B2
(en)
|
2013-03-11 |
2021-04-20 |
University Of Florida Research Foundation, Incorporated |
Delivery of card protein as therapy for occular inflammation
|
KR101905278B1
(ko)
|
2013-09-08 |
2018-10-08 |
화이자 인코포레이티드 |
나이세리아 메닌지티디스 조성물 및 그의 방법
|
EP3107939B1
(de)
|
2014-02-19 |
2020-06-17 |
University of Florida Research Foundation, Inc. |
Abgabe einer nrf2-therapie zum schutz gegen reaktive sauerstoffspezies
|
WO2016075314A1
(fr)
|
2014-11-13 |
2016-05-19 |
Institut National De La Recherche Agronomique |
Identification de facteurs de transcription de yarrowia lipolytica affectant la production de proteines
|
FR3028527A1
(fr)
|
2014-11-13 |
2016-05-20 |
Pivert |
Identification de facteurs de transcription de yarrowia lipolytica
|
EP3270959A1
(de)
|
2015-02-19 |
2018-01-24 |
Pfizer Inc |
Neisseria meningitidis-zusammensetzungen und verfahren dafür
|
SG11201906519RA
(en)
|
2017-01-31 |
2019-08-27 |
Pfizer |
Neisseria meningitidis compositions and methods thereof
|
FR3081169B1
(fr)
|
2018-05-15 |
2020-06-19 |
Messenger Biopharma |
Substitution de la coiffe des arn messagers par deux sequences d'arn introduites a leur extremite 5'
|
MX2023012608A
(es)
|
2021-04-30 |
2023-11-03 |
Kalivir Immunotherapeutics Inc |
Virus oncoliticos para la expresion modificada del mhc.
|
EP4340855A1
(de)
|
2021-08-13 |
2024-03-27 |
Triovance Holding LLC |
Hautersatzzusammensetzung und verfahren zur herstellung und verwendung davon
|